Abstract |
Liposomal irinotecan plus 5-fluorouracil/ leucovorin (nal-IRI + 5-FU/LV) has shown to provide survival benefits for patients with gemcitabine-refractory metastatic pancreatic ductal adenocarcinoma (PDAC) in NAPOLI-1 trial, in which Asian patients experienced more hematological toxicity and subsequent dose modification. A retrospective chart review to investigate the administration pattern, therapeutic efficacy and safety profile of nal-IRI + 5-FU/LV in 44 consecutive patients with gemcitabine-refractory advanced PDAC treated between December 2016 and December 2018 in National Cheng Kung University Hospital, Taiwan. Most of them had metastatic diseases (88.6%), one-line of prior treatment (72.7%), ECOG PS 0-1 (72.7%) and starting dose of nal-IRI at 60 mg/m2 (≈52 mg/m2 irinotecan free-base) in 65.9%. The overall response rate was 9.1%. The median OS was 6.6 months for the entire cohort, and 7.8 and 2.7 months for patients of ECOG PS 0-1 and>2, respectively. The median OS of ECOG PS 0-1 patients with nal-IRI starting doses at 80 mg/m2 (≈70 mg/m2 irinotecan free-base, n = 13) and 60 mg/m2 (n = 19) were 7.5 and 8.4 months, respectively. Thirty-four percent of patients experienced manageable grade 3-4 hematological toxicity. Our results confirm the clinical benefit of nal-IRI + 5-FU/LV for patients of gemcitabine-refractory advanced PDAC with good performance status in a real-world setting.
|
Authors | Yung-Yeh Su, Nai-Jung Chiang, Hui-Jen Tsai, Chia-Jui Yen, Yan-Shen Shan, Li-Tzong Chen |
Journal | Scientific reports
(Sci Rep)
Vol. 10
Issue 1
Pg. 7420
(05 04 2020)
ISSN: 2045-2322 [Electronic] England |
PMID | 32366911
(Publication Type: Journal Article)
|
Chemical References |
- Liposomes
- Topoisomerase I Inhibitors
- Irinotecan
|
Topics |
- Adenocarcinoma
(drug therapy)
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Pancreatic Ductal
(drug therapy)
- Drug Delivery Systems
- Female
- Humans
- Irinotecan
(administration & dosage)
- Kaplan-Meier Estimate
- Liposomes
(chemistry)
- Male
- Middle Aged
- Neoplasm Metastasis
- Pancreatic Neoplasms
(drug therapy)
- Patient Safety
- Retrospective Studies
- Taiwan
(epidemiology)
- Topoisomerase I Inhibitors
(administration & dosage)
- Treatment Outcome
|